🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Paclitaxel

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  2. Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion

    Ningbo Cancer Hospital

    Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less

    phase 3 small molecule active

    1 trial

  3. Paclitaxel eluting PTCA balloon

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary In-stent Restenosis

    phase 3 other active

    1 trial

  4. Paclitaxel or docetaxel + Cisplatin or carboplatin

    The First People's Hospital of Lianyungang

    Uterine Cervical Neoplasms

    phase 3 small molecule active

    1 trial

  5. Paclitaxel, Cisplatin Plus 5-FU (TCF)

    The First People's Hospital of Lianyungang

    Esophageal Cancer Stage IIB

    phase 3 other active

    1 trial

  6. Paeoniflorin + phosphatidylcholine or silymarin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis, Autoimmune

    phase 3 small molecule terminated

    1 trial

  7. Pantoprazole (Pantoloc)

    Hospital Authority, Hong Kong

    Peptic Ulcers

    phase 3 small molecule active

    1 trial

  8. Peficitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rheumatoid Arthritis (RA)

    phase 3 small molecule completed

    1 trial

  9. Pembrolizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  10. Pemetrexed 500mg/m2 iv

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 3 small molecule active

    1 trial

  11. Pemetrexed 500mg/m2 iv

    Hospital Authority, Hong Kong

    NSCLC

    phase 3 small molecule active

    1 trial

  12. Placebo

    Hospital Authority, Hong Kong

    Congenital Heart Disease in Children

    phase 3 small molecule completed

    1 trial

  13. Placebo de fasturtec, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.

    Pari Pharma GmbH

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    phase 3 small molecule active

    1 trial

  14. Placebo intramuscular injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Spontaneous Uriticaria

    phase 3 small molecule active

    1 trial

  15. Placebo tablets to match S95032 drug product are supplied as film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    Ningbo Cancer Hospital

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  16. Placebo, CEMIPLIMAB

    Ningbo Cancer Hospital

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  17. Platelet Rich Plasma

    Hospital Authority, Hong Kong

    Severe Oligoasthenoteratozoospermia

    phase 3 mab completed

    1 trial

  18. Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer Stage IIIA

    phase 3 small molecule terminated

    1 trial

  19. Posterior Approach Compression Distraction Reduction

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Basilar Invagination Associated With Atlantoaxial Dislocation

    phase 3 other active

    1 trial

  20. Pregabalin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Herpetic Neuralgia

    phase 3 small molecule active

    1 trial

  21. Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  22. Progesterone supplementation

    Hospital Authority, Hong Kong

    Assisted Reproductive Technology

    phase 3 other active

    1 trial

  23. RBC transfusion based on different protocols

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Transfusion Related Complication

    phase 3 other active

    1 trial

  24. Radiotherapy

    International Peace Maternity and Child Health Hospital

    Cervix Cancer

    phase 3 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources